MARKET

ENSC

ENSC

Ensysce Biosciences Inc
NASDAQ
2.340
+0.200
+9.35%
After Hours: 2.300 -0.04 -1.71% 19:10 05/16 EDT
OPEN
2.140
PREV CLOSE
2.140
HIGH
2.400
LOW
2.110
VOLUME
203.86K
TURNOVER
--
52 WEEK HIGH
14.67
52 WEEK LOW
1.620
MARKET CAP
5.55M
P/E (TTM)
-0.2044
1D
5D
1M
3M
1Y
5Y
1D
Ensysce Biosciences Advances in Pain Relief Innovation
TipRanks · 3d ago
Watching Ensysce Biosciences; Zacks Small-Cap Research Gives Stock $18.45 Price Valuation
Benzinga · 4d ago
Ensysce Biosciences GAAP EPS of -$1.39, revenue of $1.32M
Seeking Alpha · 4d ago
Ensysce Biosciences Shares Jump After Receiving Patent, Reporting 1Q Results
Dow Jones · 4d ago
*Ensysce Biosciences 1Q Loss/Shr $1.39 >ENSC
Dow Jones · 4d ago
Ensysce Biosciences Q1 EPS $(1.39) Beats $(3.02) Estimate, Sales $1.32M Up From $305.72K YoY
Benzinga · 4d ago
Ensysce Biosciences appoints Tracy Hysong as senior director, regulatory affairs
TipRanks · 6d ago
Weekly Report: what happened at ENSC last week (0505-0509)?
Weekly Report · 6d ago
More
About ENSC
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company develops solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. Its pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection (TAAP) platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant (MPAR) platform. Its lead product, PF614, is a TAAP extended-release oxycodone and a potential analgesic to treat severe pain. Its second product, PF614-MPAR, is to treat severe pain with the added benefit of oral overdose protection, is a combination product of the TAAP prodrug PF614 with a trypsin inhibitor. Additionally, nafamostat, which is an ingredient in its overdose protection combination products, is also being developed for the intended purpose of treating infection and pulmonary lung diseases.

Webull offers Ensysce Biosciences Inc stock information, including NASDAQ: ENSC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ENSC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ENSC stock methods without spending real money on the virtual paper trading platform.